Leerink Partners Upgrades Fulcrum Therapeutics, Inc. (FULC) to Outperform, Raises Price Target

The analyst cited a favorable risk-reward setup as the reason behind the upgrade, ahead of the trial readout for Pociredir, its lead clinical program, to treat sickle cell disease...

Keep Reading →